Agios Pharmaceuticals To Present Broad Set Of Clinical And Translational Data In Rare Blood Disorders At 65th ASH Annual Meeting and Exposition
Portfolio Pulse from Benzinga Newsdesk
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced that it will present a broad set of clinical and translational data from its programs at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition. The presentations will focus on rare blood disorders, including PK deficiency, thalassemia, sickle cell disease and anemia associated with lower-risk myelodysplastic syndromes (LR-MDS). The company's drug Mitapivat showed statistically significant hemoglobin response in Phase 2 of the RISE UP study in Sickle Cell Disease, supporting its advancement to Phase 3. Agios will also host a live and webcast investor event on Dec. 11, 2023.
November 02, 2023 | 1:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Agios Pharmaceuticals' drug Mitapivat showed promising results in Phase 2 of the RISE UP study in Sickle Cell Disease, supporting its advancement to Phase 3. This could potentially boost investor confidence in the company's research and development capabilities.
The positive results from the Phase 2 of the RISE UP study in Sickle Cell Disease for Agios Pharmaceuticals' drug Mitapivat is a significant milestone for the company. This could potentially lead to increased investor confidence in the company's research and development capabilities, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100